Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/19/2025

Fentanyl Patch Therapy Guidelines

Initiation and Dosing

  • The National Comprehensive Cancer Network recommends calculating the total 24-hour analgesic requirement of the patient's current opioid, ensuring pain is relatively well controlled on the current regimen before converting to fentanyl patch, and verifying patient is opioid-tolerant before initiating therapy 1
  • For patients on oxycodone, hydromorphone, or codeine, use a direct conversion table to select the appropriate fentanyl patch strength, and for patients on other opioids, calculate the 24-hour requirement of the current opioid, convert to equianalgesic oral morphine dose using conversion tables, and select the appropriate fentanyl patch strength based on morphine equivalence 1
  • Consider reducing the calculated equianalgesic dose by 25-50% to account for incomplete cross-tolerance between different opioids, particularly when converting from non-fentanyl opioids to fentanyl patch 1
  • The medication is indicated for patients with severe and persistent pain, defined as those taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or 60 mg oral hydrocodone per day 1
  • The National Comprehensive Cancer Network provides a conversion table to select appropriate fentanyl patch strength based on the 24-hour analgesic requirement of current opioid:
Transdermal Fentanyl Oral Morphine Oral Oxycodone Oral Hydromorphone
25 mcg/hr 60 mg/day 30 mg/day 7.5 mg/day
50 mcg/hr 120 mg/day 60 mg/day 15 mg/day
75 mcg/hr 180 mg/day 90 mg/day 22.5 mg/day
100 mcg/hr 240 mg/day 120 mg/day 30 mg/day

1

Conversion and Titration

  • When converting from continuous parenteral fentanyl infusion to transdermal fentanyl, use a 1:1 ratio (mcg/hr IV = mcg/hr transdermal) 1
  • When converting from IV morphine to IV fentanyl, the conversion ratio of 100:1 (morphine:fentanyl) should be used 1, 2
  • Prescribe short-acting opioid for breakthrough pain, especially during the first 24 hours while the patch reaches steady state, and adjust patch dosage based on average amount of breakthrough medication required after 2-3 days 1
  • Breakthrough medication should be prescribed for the first 24 hours while the patch reaches steady state, and patch dosage should be adjusted based on the average amount of breakthrough medication required after 2-3 days 1

Administration and Monitoring

  • Apply patches to clean, dry, non-irritated, flat skin on the upper torso, and each patch is typically worn for 72 hours, though some patients require replacement every 48 hours 1
  • Avoid application of heat (fever, heating pads, electric blankets) as it accelerates absorption, and monitor for respiratory depression, especially during initiation and dose increases 1
  • For dosage requirements >100 mcg/hr, use multiple patches, and remember that steady state is not reached until after 2-3 days of patch application 1
  • Patients should be monitored for respiratory depression, especially during initiation and dose increases, and high-risk situations for overdose should be avoided, including confusion between dose strengths, forgetting to remove old patches, applying multiple patches, cutting patches, and increased skin temperature, as recommended by the National Comprehensive Cancer Network 1
  • Respiratory depression is the most serious potential adverse effect of fentanyl, requiring continuous monitoring of respiratory rate and oxygen saturation, with naloxone readily available for reversal if needed, as recommended by the National Comprehensive Cancer Network 3

Special Considerations

  • Fentanyl should not be used for acute pain or postoperative pain, and is not recommended for unstable pain requiring frequent dose changes, due to its potency and potential for respiratory depression, as stated by the National Comprehensive Cancer Network 1
  • Morphine remains first-line for opioid-naïve patients, and fentanyl should be considered when patients become refractory to other opioids or develop intolerable side effects, with individual titration required, as stated by the National Comprehensive Cancer Network 3
  • Caution should be exercised when administering fentanyl to patients with hepatic impairment, and doses should be reduced due to fentanyl's metabolism in the liver, as recommended by the National Comprehensive Cancer Network 3
  • Pediatric patients require weight-based dosing, and higher doses may be required for severe cancer pain, with continuous infusion an option when patients become refractory to other opioids, as stated by the National Comprehensive Cancer Network 1
  • The American Academy of Pediatrics warns of an increased risk of respiratory depression when fentanyl is combined with other sedatives, particularly in pediatric patients, and recommends that there is no absolute maximum dose for IV fentanyl infusion, as dosing should be titrated to clinical effect while monitoring for respiratory depression and other adverse effects 4
  • The combination of fentanyl and midazolam significantly increases the risk of respiratory depression and hypoxemia, and the dose of midazolam should be reduced by 25-50% when used with opioids due to synergistic effects, as recommended by the American Gastroenterological Association 5

REFERENCES

1

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

3

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013